UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.
Utah Medical Products Reports Q2 Decline
Utah Medical Products ( NASDAQ:UTMD ) , a developer and manufacturer of specialty medical devices for women's health, neonatal, and critical care markets, released its second quarter 2025 earnings on July 24, 2025. The company reported a 4.3% decrease in GAAP revenue compared to the prior year, ...
Top Analyst Reports for JPMorgan, Novartis & AT&T
JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.
Utah Medical Q1 Earnings Drop 16% on Sales Slump, Stock Up 1%
UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.
The Zacks Analyst Blog Highlights Verizon Communications, The Southern Company, Blackstone, Utah Medical Products and The Eastern Company
Verizon Communications, The Southern Company, Blackstone, Utah Medical Products and The Eastern Company are included in this Analyst Blog.
Top Research Reports for Verizon, The Southern Co. & Blackstone
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), The Southern Company (SO) and Blackstone Inc. (BX), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and The Eastern Company (EML).
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5%
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
Utah Medical Q3 Earnings Decline Y/Y on Lower OEM Sales
UTMD reports a 5.2% EPS decline in Q3 2024, with revenues declining 20% due to reduced OEM and Filshie sales. Cost controls helped stabilize profit margins.
Chest Drainage Devices Market on Track to Hit USD 1.3 Billion by 2031, Growing at a 5.4% CAGR with a Focus on Lung Re-expansion Solutions| Analysis by Transparency Market Research, Inc.
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- According to a report published by Transparency Market Research, the global chest drainage devices market was worth US$ 799.6 Mn in 2022 and is expected to reach US$ 1.3 Bn by 2031, at a ...
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical
Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical are included in this Analyst Blog.
Top Analyst Reports for Linde, AstraZeneca & Walt Disney
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and The Walt Disney Company (DIS), as well as two micro-cap stocks FitLife Brands, Inc. (FTLF) and Utah Medical Products, Inc. (UTMD).
Utah Medical ( UTMD ) Q2 EPS Falls Y/Y on Lower Key Customer Sales
Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.
Zacks Initiates Coverage of UTMD With Neutral Recommendation
Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.
The Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace
Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace are part of the Zacks top Analyst Blog.
Top Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
StockNews.com Upgrades Utah Medical Products ( NASDAQ:UTMD ) to Strong-Buy
StockNews.com Upgrades Utah Medical Products ( NASDAQ:UTMD ) to ...
StockNews.com Upgrades Utah Medical Products ( NASDAQ:UTMD ) to Strong-Buy
Utah Medical Products ( NASDAQ:UTMD - Get Free Report ) was upgraded by StockNews.com from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Wednesday. Separately, TheStreet cut Utah Medical Products from a "b-" rating to a "c+" rating in a report on Monday, ...
Utah Medical Products ( NASDAQ:UTMD ) Upgraded to Strong-Buy by StockNews.com
StockNews.com upgraded shares of Utah Medical Products ( NASDAQ:UTMD - Free Report ) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning. Shares of NASDAQ UTMD opened at $73.38 on Friday. Utah Medical Products has a 1-year low of $72.60 and a 1-year ...
Smart Decision: Brian Koopman Acquires Utah Medical Products Stock Options - Utah Medical Products ( NASDAQ:UTMD )
A noteworthy insider acquisition was disclosed on December 26, as Koopman, Principal Financial Officer at Utah Medical Products UTMD, reported the acquisition of stock options for 500 shares.
Smoke Evacuation Systems Market Revenue to Cross USD 298.8 million by 2031, Garnering 6.6% CAGR: TMR Report
Wilmington, Delaware, United States, Oct. 30, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The smoke evacuation systems market was estimated to have acquired US$ 158.5 million in 2021. It is anticipated to register a 6.6% CAGR from 2022 to 2031, and by 2031, the market is likely ...
5 Stock Buys With Fat Profit Margins
These stocks have large profit margins, which can be a sign that a company has a unique product or is significantly ahead of its competitors.
Smoke Evacuation Systems Market on Track to Attain US$ 298.8 Million by 2031, Fueled by a 6.6% CAGR - Transparency Market Research Inc.
Wilmington, Delaware, United States, Aug. 25, 2023 ( GLOBE NEWSWIRE ) -- The global market for smoke evacuation systems was projected to have a market value worth US$ 158.5 million in 2021. The market is anticipated to advance with a 6.6% CAGR from 2022 to 2031 and by 2031.
Analyst Insights: Seizert Capital Partners LLC Reduces Stake in Utah Medical Products, StockNews.com Downgrades Rating, and Quarterly Dividend Announcement
Analyst Insights: Seizert Capital Partners LLC Reduces Stake in Utah Medical Products, StockNews.com Downgrades ...
Analyst Insights: Seizert Capital Partners LLC Reduces Stake in Utah Medical Products, StockNews.com Downgrades Rating, and Quarterly Dividend Announcement
Analyst Insights: Seizert Capital Partners LLC Reduces Stake in Utah Medical Products, StockNews.com Downgrades ...
Chest Drainage Devices Market Set to Reach US$ 1.3 Billion by 2031 with Remarkable 5.4% CAGR Expansion: TMR Study
Wilmington, Delaware, United States, Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- The market for chest drainage devices was estimated to have garnered a global market valuation around US$ 799.6 million in 2022.
Utah Medical Products ( NASDAQ:UTMD ) Lowered to "Buy" at StockNews.com
StockNews.com lowered shares of Utah Medical Products ( NASDAQ:UTMD - Free Report ) from a strong-buy rating to a buy rating in a research report released on Tuesday. Shares of NASDAQ UTMD opened at $97.40 on Tuesday. Utah Medical Products has a twelve month low of $80.68 and a twelve month ...
UTMD: Find out the 3 Medical Stocks Smart Money is Chasing
The medical sector is poised for growth with rising healthcare demand due to an aging population and technological advancements. Moreover, institutional investors are drawn to the industry's stability and growth potential, driven by inelastic demand for its products and services.
VMW: 3 Quality Stocks to Invest in Now
The current market outlook remains uncertain due to factors such as high inflation and concerns about a potential economic downturn, causing investors to feel less confident about the market's near-term future.
UMC: Need Stability? 3 Stocks to Buy
The stubbornly high inflation, strong jobs growth, restrictive monetary policy, and tightening of lending standards point to a recession later this year. The recession fears may drive the stock market turbulence and could continue to prevent investors from taking strategic investment decisions.
ABT: Best Medical Stock Investors Should Buy in a Recession
Inflation remains way above the Fed's 2% target despite cooling down. Moreover, although the central bank has indicated a rate hike pause, a cut is not in sight. Amid this, the stable demand for healthcare products should help fundamentally sound medical stock Abbott Laboratories ( ABT ) perform ...
SNN: Add This Top Equipment Stock to Your Portfolio for a Strong Week Ahead
SNN: Add This Top Equipment Stock to Your Portfolio for a Strong ... ...
Advanced Medical Stopcock Market Share ( $1.23 Billion by 2028 ) Lead by Asia Pacific Region ( 5.1% CAGR ) - Growth Report by The Insight Partners
New York, Feb. 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, "Advanced Medical Stopcock Market Size, Share, Growth and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Low-Pressure Stopcock, Medium-Pressure Stopcock, and High-Pressure Stopcock ) , End ...
ABT: 3 Medical Device Stocks to Watch Right Now
The medical device industry produces various devices used in day-to-day healthcare. The industry gained significant investors' attention during the pandemic due to the rising sales of medical devices related to COVID-19 prevention and management.
ABT: Is It Too Late to Make Money on ABT Stocks This Fall?
Healthcare giant Abbott Laboratories ( ABT ) has increased its projected adjusted EPS from $5.17 to $5.23 for 2022. "Our results and increased guidance in the current macroeconomic environment reflect the strength of our diversified business model and execution," Robert B.
Utah Medical Products ( NASDAQ:UTMD ) Coverage Initiated at StockNews.com
Investment analysts at StockNews.com initiated coverage on shares of Utah Medical Products ( NASDAQ:UTMD - Get Rating ) in a research report issued to clients and investors on Wednesday. The firm set a "strong-buy" rating on the medical instruments supplier's stock.
Peritoneal Dialysis Market is expected to generate a revenue of USD 150.20 Billion by 2030, Globally, at 6.47% CAGR: Verified Market Research®
Jersey City, New Jersey, Sept. 21, 2022 ( GLOBE NEWSWIRE ) -- Verified Market Research recently published a report, "Peritoneal Dialysis Market" By Treatment Type ( , ) , By Product Type ( Peritoneal Dialysis Solution, Device ) , By End-User ( Home-Based Dialysis, Dialysis Center And Hospital ...
BFLY: Cathie Wood Is Building up Her Stake in This Stock. Should You?
Butterfly Network ( BFLY ) is a digital health company that develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company provides Butterfly iQ, a handheld and single-probe whole body ultrasound system.
EAR: Should You Buy Eargo After the FDA Ruling on Hearing Aids?
San Jose, California-based Eargo, Inc. ( EAR ) is a medical device company that markets and sells hearing aids in the United States. Its hearing aids are virtually invisible, rechargeable, and completely-in-the-canal devices indicated to compensate for mild to moderate hearing loss.
ABT: 2 Medical Stocks That Are Attractive Buys Right Now
Inelastic demand, rising investments, and consistent breakthroughs make healthcare stocks attractive to investors amid these uncertain market conditions. Moreover, the growing demand for medical products and services from an aging population should drive revenue growth for companies in this space.
New Study from StrategyR Highlights a $223.4 Million Global Market for Smoke Evacuation Systems by 2026
• Access to our digital archives and MarketGlass Research Platform Companies: 42 - Players covered include Bovie Medical Corporation. Buffalo Filter LLC. Cls Surgimedics. ConMed Corporation. CooperSurgical, Inc. ERBE Elektromedizin GmbH. I. C. Medical, Inc. Medtronic PLC.
EGHSF: 3 Top-Rated Stocks to Buy and Hold Forever
The Federal Reserve's aggressive interest rate hikes to ease the inflationary pressure have increased the odds of the economy slipping into a recession. Massive market volatility and sell-offs have recently lowered the valuations of many quality stocks.
